Imigran Subject

Sumatriptan, the active ingredient in Imigran, is a selective serotonin (5‑HT1B/1D) receptor agonist presented as a subcutaneous injection for subcutaneous use. It treats acute migraine attacks in adults.

GNH USA supplies Imigran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan is a triptan medication used for acute headache disorders that involve the trigeminovascular pathway.

Migraine (with or without aura): provides rapid relief of headache pain, photophobia, phonophobia and nausea. Migraine with severe nausea: reduces associated gastrointestinal symptoms while alleviating pain. Cluster headache: can abort acute cluster attacks when administered subcutaneously.

Sumatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain or erythema - Tingling or numbness (paraesthesia) - Warmth or flushing sensation - Dizziness or light‑headedness - Nausea or mild gastrointestinal upset - Transient chest tightness

Serious or Rare Side Effects: - Chest pain or myocardial ischemia - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with other serotonergic drugs - Allergic reactions including anaphylaxis - Ischemic stroke or transient ischemic attack - Severe arrhythmias or cardiac conduction abnormalities

Before prescribing Sumatriptan, clinicians should evaluate cardiovascular risk and contraindications.

Assess cardiovascular history: avoid in patients with known coronary artery disease. Control hypertension: do not use in uncontrolled high blood pressure. Use caution in ischemic heart disease: monitor for chest discomfort. Avoid serotonergic drug combinations: monitor for serotonin syndrome. Check for hypersensitivity: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sumatriptan can interact with several medication classes, requiring careful assessment.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension. - SSRIs, SNRIs, or other serotonergic agents: potential serotonin syndrome. - Ergot alkaloids: additive vasoconstriction. - Other triptans: cumulative vasoconstrictive effect. - Linezolid: increased serotonin toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers or other antihypertensives: may enhance blood pressure lowering. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels.